Transcripts DocMorris AG

Stocks

ROSE

CH0042615283

Drug Retailers

Market Closed - Swiss Exchange 18:30:38 27/08/2026 +03			5-day change	1st Jan Change
10.64 ^CHF	+3.80%		+3.10%	+78.82%

08-26	DocMorris AG : From a Buy to Neutral rating by Jefferies	ZD
08-26	Swiss stocks - Factors to watch on August 26	RE

Transcripts

08-21	DocMorris AG, H1 2026 Earnings Call, Aug 19, 2026
04-17	DocMorris AG, Q1 2026 Sales/ Trading Statement Call, Apr 16, 2026
03-24	DocMorris AG, 2025 Earnings Call, Mar 19, 2026
20/08/25	DocMorris AG, H1 2025 Earnings Call, Aug 19, 2025
10/04/25	DocMorris AG, Q1 2025 Sales/ Trading Statement Call, Apr 10, 2025
13/03/25	DocMorris AG, 2024 Earnings Call, Mar 13, 2025
20/08/24	DocMorris AG, H1 2024 Earnings Call, Aug 20, 2024
21/03/24	DocMorris AG, 2023 Earnings Call, Mar 21, 2024
17/08/23	Zur Rose Group AG, H1 2023 Earnings Call, Aug 17, 2023
23/03/23	Zur Rose Group AG, 2022 Earnings Call, Mar 23, 2023
18/08/22	Zur Rose Group AG, H1 2022 Earnings Call, Aug 18, 2022
24/03/22	Zur Rose Group AG, 2021 Earnings Call, Mar 24, 2022
21/10/21	Zur Rose Group AG Provides Revenue Guidance for the Year 2021	CI
18/08/21	Zur Rose Group AG, H1 2021 Earnings Call, Aug 18, 2021
18/08/21	Zur Rose Group AG Re-Affirm Earnings Guidance for the Year 2021	CI
16/06/21	Zur Rose Group AG - Analyst/Investor Day
18/03/21	Zur Rose Group AG, 2020 Earnings Call, Mar 18, 2021
18/03/21	Zur Rose Group AG Provides Earnings Guidance for the Year 2021	CI
21/10/20	Zur Rose Group AG Confirms Earnings Outlook for the Full Year 2020	CI
19/08/20	Zur Rose Group AG, H1 2020 Earnings Call, Aug 19, 2020
19/08/20	Zur Rose Group AG Provides Revenue Guidance for the Fiscal 2020	CI
16/07/20	Zur Rose Group AG Provides Consolidated Earnings Revenue Guidance for the First Half Ended June 30, 2020	CI
19/03/20	Zur Rose Group AG, 2019 Earnings Call, Mar 19, 2020
23/10/19	Zur Rose Group Ag Provides Earnings Guidance for the Full Year 2019; Provides Earnings Guidance for 2022	CI
17/04/19	Zur Rose Group Ag Announces Revenue Results for the First Quarter 2019; Reaffirms Guidance for the Group for 2019	CI